Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology, Fibrosis, and Vascular Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for PDGFRB drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PDGFRB ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified, HEK293 Expressed (Native Glycosylation). |
View PDGFRB Products |
| Gene Delivery | PDGFRB Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View PDGFRB Products |
| Benchmark Ab | Anti-PDGFRB (Sequence Verified Biosimilar) Recombinant positive control for assay calibration. |
View PDGFRB Products |
| Validator | PDGFRB siRNA Set For knockdown verification and specificity checks. |
View PDGFRB Products |
| Related Target A | PDGFRA Subfamily selectivity counter-screening and heterodimer pairing. |
View PDGFRA Products |
| Related Target B | VEGFR2 (KDR) Synergistic angiogenesis pathway targeting. |
View VEGFR2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Subfamily Counter-Screening (PDGFRA vs PDGFRB) | Homolog panel proteins strictly verified by mass spec and sequence analysis. |
| Cross-Species Tox Evaluation | Human/Mouse/Cyno ortholog proteins available with >95% purity and theoretical MW confirmation. |
| Lack of Reliable Assay Controls | Sequence-verified clinical benchmark antibodies included for baseline standardizations. |
| False Positives in Functional Assays | High purity reagents (<1EU/ug Endotoxin) and validated siRNA included for specificity checks. |
Live PDGFRB R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PDGFRB therapeutics is intensifying, with major players shifting focus from traditional broad-spectrum tyrosine kinase inhibitors (TKIs) to highly selective monoclonal antibodies and Antibody-Drug Conjugates (ADCs). As a primary marker for pericytes and Cancer-Associated Fibroblasts (CAFs), PDGFRB is becoming a critical target for depleting the tumor stroma, thereby enhancing the penetration and efficacy of combination immunotherapies. As first-generation multi-kinase inhibitors reach maturity, the next wave of R&D is aggressively targeting highly selective allosteric modulation and stromal-targeted payload delivery to overcome solid tumor microenvironment barriers.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC / Stromal Targeting | Leading Biopharmas | Solid Tumors (Stroma-rich) | Internalization Assay (Need high-purity, natively glycosylated ECD-Fc) |
| Monoclonal Antibody | Eli Lilly, Regeneron | Fibrosis, Ophthalmology | Selectivity Assay (Need Cross-reactive Abs & PDGFRA counter-screens) |
| Small Molecule (Selective TKI) | Novartis, Blueprint Medicines | Leukemia, Soft Tissue Sarcoma | Resistance Mapping (Need Sequence-Verified Mutant Proteins) |
| Bispecifics | Emerging Biotechs | Oncology | Heterodimer Validation (Need distinct, high-purity orthologs) |